Breast Cancer
Modified weekly docetaxel schedule evaluated in elderly breast cancer patients
Published in Women's Health Weekly, September 15th, 2005
"Standard dose docetaxel is burdened by severe toxicity. Weekly schedules have been shown to be active as standard scheme with reduced side effects," investigators in Italy reported.
"In 20-30% of elderly pts the classic 6-week schedule induces grade 3/4 fatigue and other cumulative toxicities. We carried out this safety study in order to evaluate whether a modified weekly docetaxel schedule would improve the toxicity profile. Twenty-one untreated elderly ({{>=}}70 years) pts suffering from metastatic breast cancer were enrolled in...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
More Articles from Women's Health Weekly
- Breast Cancer
Computer program complements genetic counseling for breast cancer risk - Cervical Cancer
Capecitabine studied for treatment in recurrent squamous cell cervical carcinoma - Complementary & Alternative Medicine
Natural compounds studied as substitutes for hormone replacement therapy - Endometrial Cancer
Factors influencing vaginal relapse in stage I endometrial cancer - Menopause
Physiology of hot flashes discussed in women's health publication - Adverse Drug Reaction
Agency strengthens risk management program for Isotretinoin - More from this issue of Women's Health Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
